[{"NetIncomeLoss_1_Q3_USD":-3175000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":14486000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":958000.0,"FairValueLiabilitiesLevel2ToLevel1TransfersAmount_0_Q3_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-22897000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q3_USD":16195000.0,"AssetsCurrent_0_Q3_USD":418412000.0,"OperatingLeaseExpense_3_Q3_USD":4200000.0,"OperatingLeaseExpense_1_Q3_USD":1400000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_3_Q3_USD":166547000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":26702000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":1227000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q3_USD":12694000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3_Q3_USD":279000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q3_USD":-379000.0,"EquitySecuritiesFvNi_0_Q3_USD":1900000.0,"Assets_0_Q3_USD":474112000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-379000.0,"ShareBasedCompensation_3_Q3_USD":12743000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":0.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"LongTermDebtFairValue_0_Q3_USD":45900000.0,"CommitmentsAndContingencies_0_Q3_USD":0.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":68279.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":62406.0,"ResearchAndDevelopmentExpense_1_Q3_USD":24202000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":222404000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3_Q3_USD":148147000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_3_Q3_USD":900000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_1_Q3_USD":500000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":5645000.0,"AccountsReceivableNetCurrent_0_Q3_USD":4965000.0,"CommonStockValue_0_Q3_USD":70000.0,"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1_Q3_USD":0.0,"DepreciationDepletionAndAmortization_3_Q3_USD":1360000.0,"ConvertibleDebtFairValueDisclosures_0_Q3_USD":308400000.0,"ProceedsFromIssuanceOfPrivatePlacement_3_Q3_USD":36225000.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_3_Q3_USD":0.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-83081000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-3554000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":200812000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":1096953000.0,"Liabilities_0_Q3_USD":324507000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3_Q3_USD":3224000.0,"OperatingLeaseLiability_0_Q3_USD":4460000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":38912000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":12302000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":230483000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":67730000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q3_USD":277000.0,"IncreaseDecreaseInAccountsPayableTrade_3_Q3_USD":-1422000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3_Q3_USD":0.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q3_USD":4616000.0,"LiabilitiesCurrent_0_Q3_USD":27573000.0,"AccountsPayableCurrent_0_Q3_USD":6738000.0,"NonoperatingIncomeExpense_3_Q3_USD":3183000.0,"NonoperatingIncomeExpense_1_Q3_USD":1078000.0,"InterestExpense_3_Q3_USD":11945000.0,"InterestExpense_1_Q3_USD":3976000.0,"IncreaseDecreaseInContractWithCustomerAsset_3_Q3_USD":0.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":3183000.0,"LongTermDebtNoncurrent_0_Q3_USD":45920000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":1437000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q3_pure":0.09,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":200812000.0,"ProceedsFromDebtNetOfIssuanceCosts_3_Q3_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_3_Q3_USD":0.0,"OperatingLeasePayments_3_Q3_USD":5200000.0,"DebtSecuritiesAvailableForSaleGainLoss_3_Q3_USD":0.0,"DebtSecuritiesAvailableForSaleGainLoss_1_Q3_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":7667000.0,"NetIncomeLoss_3_Q3_USD":-83360000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-43207000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":4692000.0,"AmortizationOfFinancingCosts_1_Q3_USD":20000.0,"FairValueLiabilitiesLevel1ToLevel2TransfersAmount_0_Q3_USD":0.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":49106000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":41688000.0,"OperatingIncomeLoss_3_Q3_USD":-57536000.0,"OperatingIncomeLoss_1_Q3_USD":5184000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":209452000.0,"AvailableForSaleSecuritiesNoncurrent_0_Q3_USD":40958000.0,"PreferredStockValue_0_Q3_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":474112000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":10045000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":3943000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q3_USD":16648000.0,"OperatingExpenses_3_Q3_USD":106642000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3_Q3_USD":1106000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.34,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.05,"ProfitLoss_3_Q3_USD":-83360000.0,"OtherLiabilitiesCurrent_0_Q3_USD":2406000.0,"StockholdersEquity_0_Q3_USD":149605000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":4497000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-948376000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":164379000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":-198000.0,"OperatingExpenses_1_Q3_USD":36504000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":1332000.0,"Ticker":"CYTK","CIK":"1061983","name":"CYTOKINETICS INC","OfficialName":"Cytokinetics Incorporated Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3243164482.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201106"}]